Predictive Oncology Inc. (POAI)
NASDAQ: POAI · Real-Time Price · USD
1.520
+0.070 (4.83%)
At close: Mar 31, 2025, 4:00 PM
1.473
-0.047 (-3.11%)
Pre-market: Apr 1, 2025, 5:54 AM EDT
Predictive Oncology Revenue
Predictive Oncology had revenue of $345.69K in the quarter ending September 30, 2024, a decrease of -48.91%. This brings the company's revenue in the last twelve months to $1.48M, down -11.21% year-over-year. In the year 2023, Predictive Oncology had annual revenue of $1.78M with 18.24% growth.
Revenue (ttm)
$1.48M
Revenue Growth
-11.21%
P/S Ratio
4.92
Revenue / Employee
$42,406
Employees
35
Market Cap
10.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.78M | 274.63K | 18.24% |
| Dec 31, 2022 | 1.51M | 84.78K | 5.97% |
| Dec 31, 2021 | 1.42M | 168.41K | 13.45% |
| Dec 31, 2020 | 1.25M | -159.29K | -11.28% |
| Dec 31, 2019 | 1.41M | -90.00 | -0.01% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
POAI News
- 6 days ago - Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary - GlobeNewsWire
- 11 days ago - Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries - GlobeNewsWire
- 5 weeks ago - Predictive Oncology Closes Registered Direct Offering - GlobeNewsWire
- 5 weeks ago - Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing - GlobeNewsWire
- 6 weeks ago - Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform - Business Wire
- 2 months ago - AIRNA Appoints Matthew Hawryluk as Chief Business Officer - Business Wire
- 2 months ago - Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay - GlobeNewsWire
- 2 months ago - PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI - Business Wire